Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Queensland Health
Citi
Harvard Business School
McKesson
Express Scripts
Cipla
Medtronic
Healthtrust

Generated: June 24, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,153,222

« Back to Dashboard

Summary for Patent: 5,153,222
Title: Method of treating pulmonary hypertension with benzidine prostaglandins
Abstract:The present invention is concerned with methods for the prophylaxis, treatment and diagnosis of pulmonary hypertension which comprise the administrative of an effective amount of a compound of formula (I) ##STR1## wherein a is an integer of from 1 to 3; X and Y, which may be the same or different, are selected from --O-- and --CH.sub.2 --; R is --(CH.sub.2).sub.5 R.sup.1 wherein R.sup.1 is hydrogen or methyl, or R is cyclohexyl, or R is --CH(CH.sub.3)CH.sub.2 C.tbd.CCH.sub.3 ; and the dotted line represents an optional double bond; or of a physiologically acceptable salt or acid derivative thereof. Medicaments and diagnostic aids for use in the methods of the invention are also within the scope of the invention.
Inventor(s): Tadepalli; Anjaneyulu S. (Durham, NC), Long; Walker A. (Chapel Hill, NC), Crow; James W. (Raleigh, NC), Klein; Kenneth B. (Chapel Hill, NC)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:07/715,439
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,153,222
Patent Claims: 1. A method of treating pulmonary hypertension in a patient, which comprises administering to said patient an effective pulmonary hypertension treatment amount of the compound 9-deoxy-2',9.alpha.-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)- 13,14-dihydro-prostaglandin F.sub.1.

2. A method of treating pulmonary hypertension in a patient, which comprises administering to said patient an effective pulmonary hypertension treatment amount of a pharmaceutically acceptable salt of the compound 9-deoxy-2',9.alpha.-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylene)- 13,14-dihydroprostaglandin F.sub.1.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Moodys
Chinese Patent Office
Chubb
Colorcon
Daiichi Sankyo
Federal Trade Commission
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.